Skip to main content
SpringerLink
Log in

Pathology of B-Cell Non-Hodgkin’s Lymphomas and Multiple Myeloma

  • Chapter
Hodgkin’s and Non-Hodgkin’s Lymphoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 131))

Abstract

B-cell non-Hodgkin’s lymphomas (B-NHLs) represent a heterogeneous group of neoplasms with respect to their clinical manifestations, histopathologic features, and biological behavior. The now widely utilized World Health Organization (WHO) classification scheme incorporates our current knowledge of the clinical and pathological features of B-cell neoplasms, and categorizes them into distinct entities (Table 1).1,2 It is now generally accepted that B-NHLs arise from neoplastic transformation of B-cells at specific stages of differentiation, although the normal counterparts for some B-NHLs have not been clearly delineated (e.g. hairy cell leukemia). Furthermore, some entities, such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), appear to resemble more than one B-cell differentiation stage. Nevertheless, a basic understanding of B-cell differentiation stages and their associated immunophenotypic characteristics facilitates accurate diagnosis and appropriate management of B-NHLs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

11. References

  1. Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J.W., (eds.). “World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.” IARC Press, Lyon, 2001.

    Google Scholar 

  2. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392.

    PubMed  CAS  Google Scholar 

  3. Gathings WE, Lawton AR, Cooper MD. Immunofluorescent studies of the development of pre-B cells, B lymphocytes and immunoglobulin isotype diversity in humans. Eur J Immunol. 1977;7:804–810.

    Article  PubMed  CAS  Google Scholar 

  4. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood. 2002;99:409–426.

    Article  PubMed  CAS  Google Scholar 

  5. Torlakovic E, Torlakovic G, Nguyen PL et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343–1350.

    Article  PubMed  Google Scholar 

  6. Korsmeyer SJ, Hieter PA, Ravetch JV et al. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci U S A. 1981;78:7096–7100.

    Article  PubMed  CAS  Google Scholar 

  7. Expression of cytoplasmic CD22 in B-cell ontogeny. In “Leukocyte Typing III: White Cell Differentiation Antigens.” (McMichael A.J., Beverley P.C.L., Cobbold S. et al., eds.) 474–476. Oxford University Press, Oxford, 1987.

    Google Scholar 

  8. Anderson KC, Bates MP, Slaughenhoupt BL et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424–1433.

    PubMed  CAS  Google Scholar 

  9. Foon KA, Todd RF, III. Immunologic classification of leukemia and lymphoma. Blood. 1986;68:1–31.

    PubMed  CAS  Google Scholar 

  10. Nadler LM, Korsmeyer SJ, Anderson KC et al. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984;74:332–340.

    Article  PubMed  CAS  Google Scholar 

  11. Krenacs L, Himmelmann AW, Quintanilla-Martinez L et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 1998;92:1308–1316.

    PubMed  CAS  Google Scholar 

  12. Klein B, Tarte K, Jourdan M et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78:106–113.

    PubMed  CAS  Google Scholar 

  13. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000;343:37–49.

    Article  PubMed  CAS  Google Scholar 

  14. Knowles DM. Immunophenotypic markers. In “Neoplastic Hematopathology.” (Knowles D.M., ed.) 93–226. Lippincott Williams & Wilkins, Philadelphia, 2001.

    Google Scholar 

  15. Mason DY, van Noesel CJ, Cordell JL et al. The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation. Eur J Immunol. 1992;22:2753–2756.

    Article  PubMed  CAS  Google Scholar 

  16. Kipps TJ. The CD5 B cell. Adv Immunol. 1989;47:117–185.

    PubMed  CAS  Google Scholar 

  17. Inghirami G, Foitl DR, Sabichi A et al. Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. Blood. 1991;78:1503–1515.

    PubMed  CAS  Google Scholar 

  18. MacLennan IC, Gulbranson-Judge A, Toellner KM et al. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev. 1997;156:53–66.

    Article  PubMed  CAS  Google Scholar 

  19. Kraal G, Hardy RR, Gallatin WM et al. Antigen-induced changes in B cell subsets in lymph nodes: analysis by dual fluorescence flow cytofluorometry. Eur J Immunol. 1986;16:829–834.

    Article  PubMed  CAS  Google Scholar 

  20. Kraal G, Weissman IL, Butcher EC. Germinal centre B cells: antigen specificity and changes in heavy chain class expression. Nature. 1982;298:377–379.

    Article  PubMed  CAS  Google Scholar 

  21. Cattoretti G, Chang CC, Cechova K et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45–53.

    PubMed  CAS  Google Scholar 

  22. Hanna MG. An autoradiographic study of the germinal center in spleen white pulp during early intervals of the immune response. Lab Invest. 1964;13:95–104.

    PubMed  Google Scholar 

  23. Liu YJ, Mason DY, Johnson GD et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol. 1991;21:1905–1910.

    Article  PubMed  CAS  Google Scholar 

  24. MacLennan IC. Germinal centers. Annu Rev Immunol. 1994;12:117–139.

    Article  PubMed  CAS  Google Scholar 

  25. Pittaluga S, Ayoubi TA, Wlodarska I et al. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin’s lymphomas. J Pathol. 1996;179:145–150.

    Article  PubMed  CAS  Google Scholar 

  26. Liu YJ, Zhang J, Lane PJ et al. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol. 1991;21:2951–2962.

    Article  PubMed  CAS  Google Scholar 

  27. Dogan A, Bagdi E, Munson P et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846–852.

    Article  PubMed  CAS  Google Scholar 

  28. Spencer J, Finn T, Pulford KA et al. The human gut contains a novel population of B lymphocytes which resemble marginal zone cells. Clin Exp Immunol. 1985;62:607–612.

    PubMed  CAS  Google Scholar 

  29. van den Oord JJ, Wolf-Peeters C, Desmet VJ. The marginal zone in the human reactive lymph node. Am J Clin Pathol. 1986;86:475–479.

    PubMed  Google Scholar 

  30. van Krieken JH, von Schilling C, Kluin PM et al. Splenic marginal zone lymphocytes and related cells in the lymph node: a morphologic and immunohistochemical study. Hum Pathol. 1989;20:320–325.

    Article  PubMed  Google Scholar 

  31. Barker HF, Hamilton MS, Ball J et al. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992;81:331–335.

    PubMed  CAS  Google Scholar 

  32. Harada H, Kawano MM, Huang N et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658–2663.

    PubMed  CAS  Google Scholar 

  33. Ridley RC, Xiao H, Hata H et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81:767–774.

    PubMed  CAS  Google Scholar 

  34. Brunning RD, Borowitz MJ, Matutes E et al. Precursor lymphoblastic leukaemia/lymphoblastic lymphoma (precursor B-cell acute lymphoblastic leukaemia). In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.” (Jaffe E.S., Harris N.L., Stein H. et al., eds.) 111–114. IARC Press, Lyon, 2001.

    Google Scholar 

  35. Knowles DM. Lymphoblastic lymphoma. In “Neoplastic Hematopathology.” (Knowles D.M., ed.) 915–951. Lippincott Williams & Wilkins, Philadelphia, 2001.

    Google Scholar 

  36. Ludwig WD, Rieder H, Bartram CR et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898–1909.

    PubMed  CAS  Google Scholar 

  37. Johansson B, Moorman AV, Haas OA et al. Hematologic malignancies with t(4;11)(q21;q23)—a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia. 1998;12:779–787.

    Article  PubMed  CAS  Google Scholar 

  38. Parkin JL, Arthur DC, Abramson CS et al. Acute leukemia associated with the t(4;11) chromosome rearrangement: ultrastructural and immunologic characteristics. Blood. 1982;60:1321–1331.

    PubMed  CAS  Google Scholar 

  39. Schardt C, Ottmann OG, Hoelzer D et al. Acute lymphoblastic leukemia with the (4;11) translocation: combined cytogenetic, immunological and molecular genetic analyses. Leukemia. 1992;6:370–374.

    PubMed  CAS  Google Scholar 

  40. Ludwig WD, Bartram CR, Harbott J et al. Phenotypic and genotypic heterogeneity in infant acute leukemia. I. Acute lymphoblastic leukemia. Leukemia. 1989;3:431–439.

    PubMed  CAS  Google Scholar 

  41. Acute Lymphoblastic Lymphoma In “Bone Marrow Pathology” (Foucar K., ed.) 485–514. ASCP Press, Chicago, 2001.

    Google Scholar 

  42. Faderl S, Kantarjian HM, Talpaz M et al. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91:3995–4019.

    PubMed  CAS  Google Scholar 

  43. Crist WM, Carroll AJ, Shuster JJ et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 1990;76:117–122.

    PubMed  CAS  Google Scholar 

  44. Lampert F, Harbott J, Ritterbach J et al. Karyotypes in acute childhood leukemias may lose prognostic significance with more intensive and specific chemotherapy. Cancer Genet Cytogenet. 1991;54:277–279.

    Article  PubMed  CAS  Google Scholar 

  45. Vasef MA, Brynes RK, Murata-Collins JL et al. Surface immunoglobulin light chain-positive acute lymphoblastic leukemia of FAB L1 or L2 type: a report of 6 cases in adults. Am J Clin Pathol. 1998;110:143–149.

    PubMed  CAS  Google Scholar 

  46. Li S, Lew G. Is B-lineage acute lymphoblastic leukemia with a mature phenotype and 11 morphology a precursor B-lymphoblastic leukemia/lymphoma or Burkitt leukemia/lymphoma? Arch Pathol Lab Med. 2003;127:1340–1344.

    PubMed  Google Scholar 

  47. Talmant P, Berger R, Robillard N et al. Childhood B-cell acute lymphoblastic leukemia with FAB-LI morphology and a t(9;11) translocation involving the MLL gene. Hematol Cell Ther. 1996;38:265–268.

    Article  PubMed  CAS  Google Scholar 

  48. Tsao L, Draoua HY, Osunkwo I et al. Mature B-cell acute lymphoblastic leukemia with t(9;11) translocation: a distinct subset of B-cell acute lymphoblastic leukemia, Mod Pathol. 2004;17:832–839.

    Article  PubMed  Google Scholar 

  49. Alessandri AJ, Reid GS, Bader SA et al. ETV6 (TEL)-AMLl pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. Br J Haematol. 2002;116:266–272.

    PubMed  Google Scholar 

  50. Rubnitz JE, Camitta BM, Mahmoud H et al. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J Clin Oncol.1999;17:191–196.

    PubMed  CAS  Google Scholar 

  51. De Zen L, Orfao A, Cazzaniga G et al. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia. 2000;14:1225–1231.

    Article  PubMed  CAS  Google Scholar 

  52. Harris NL. Mature B-cell neoplasms: Introduction. In “World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.” (Jaffe E.S., Harris N.L., Stein H. et al., eds.) IARC Press, Lyon, 2001.

    Google Scholar 

  53. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849.

    PubMed  CAS  Google Scholar 

  54. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood. 1994;84:1361–1392.

    PubMed  CAS  Google Scholar 

  55. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.

    Article  PubMed  CAS  Google Scholar 

  56. Muller-Hermelink HK, Catovsky D, Monrserrat E et al. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.” (Jaffe E.S., Harris N.L., Stein H. et al., eds.) 127–130. IARC Press, Lyon, 2001.

    Google Scholar 

  57. Rozman C, Hernandez-Nieto L, Montserrat E et al. Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia. Br J Haematol. 1981;47:529–537.

    PubMed  CAS  Google Scholar 

  58. Geisler C, Ralfkiaer E, Hansen MM et al. The bone marrow histological pattern has independent prognostic value in early stage chronic lymphocytic leukaemia. Br J Haematol. 1986;62:47–54.

    PubMed  CAS  Google Scholar 

  59. Matutes E, Oscier D, Garcia-Marco J et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996;92:382–388.

    Article  PubMed  CAS  Google Scholar 

  60. Foucar K. Chronic lymphoid leukemias and lymphoproliferative disorders. Mod Pathol. 1999;12:141–150.

    PubMed  CAS  Google Scholar 

  61. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol. 2000;4:22–47.

    Article  PubMed  CAS  Google Scholar 

  62. MacLennan IC, Liu YJ, Oldfield S et al. The evolution of B-cell clones. Curr Top Microbiol Immunol. 1990;159:37–63.

    PubMed  CAS  Google Scholar 

  63. Klein U, Tu Y, Stolovitzky GA et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625–1638.

    Article  PubMed  CAS  Google Scholar 

  64. Hamblin TJ, Davis Z, Gardiner A et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854.

    PubMed  CAS  Google Scholar 

  65. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775.

    Article  PubMed  CAS  Google Scholar 

  66. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847.

    PubMed  CAS  Google Scholar 

  67. Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944–4951.

    Article  PubMed  CAS  Google Scholar 

  68. Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–1029.

    Article  PubMed  CAS  Google Scholar 

  69. Thunberg U, Johnson A, Roos G et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood. 2001;97:1892–1894.

    Article  PubMed  CAS  Google Scholar 

  70. Durig J, Nuckel H, Cremer M et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 2003;17:2426–2434.

    Article  PubMed  CAS  Google Scholar 

  71. Del Poeta G, Maurillo L, Venditti A et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98:2633–2639.

    Article  PubMed  Google Scholar 

  72. Orchard JA, Ibbotson RE, Davis Z et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105–111.

    Article  PubMed  CAS  Google Scholar 

  73. de Melo N, Matutes E, Cordone I et al. Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders. J Clin Pathol. 1992;45:660–663.

    Article  PubMed  Google Scholar 

  74. Astsaturov IA, Samoilova RS, Iakhnina EI et al. The relevance of cytological studies and Ki-67 reactivity to the clinical course of chronic lymphocytic leukemia. Leuk Lymphoma. 1997;26:337–342.

    PubMed  CAS  Google Scholar 

  75. Cordone I, Masi S, Mauro FR et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998;91:4342–4349.

    PubMed  CAS  Google Scholar 

  76. Foucar K. B-cell chronic lymphocytic and prolymphocytic leukemia. In “Neoplastic Hematopathology.” (Knowles D.M., ed.)1505–1529. Lippincott Williams & Wilkins, Philadelphia, 2001.

    Google Scholar 

  77. Swerdlow SH, Berger F, Isaacson PG et al. Mantle cell lymphoma. In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.” (Jaffe E.S., Harris N.L., Stein H. et al., eds.)168–170. IARC Press, Lyon, 2001.

    Google Scholar 

  78. Gu J, Huh YO, Jiang F et al. Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings. Mod Pathol. 2004;17:553–560.

    Article  PubMed  Google Scholar 

  79. Dorfman DM, Pinkus GS. Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23. Mod Pathol. 1994;7:326–331.

    PubMed  CAS  Google Scholar 

  80. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol. 1996;105:451–457.

    PubMed  CAS  Google Scholar 

  81. Xu Y, McKenna RW, Kroft SH. Assessment of CD10 in the diagnosis of small B-cell lymphomas: a multiparameter flow cytometric study. Am J Clin Pathol. 2002;117:291–300.

    Article  PubMed  Google Scholar 

  82. Zukerberg LR, Medeiros LJ, Ferry JA et al. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol. 1993;100:373–385.

    PubMed  CAS  Google Scholar 

  83. Falini B, Fizzotti M, Pileri S et al. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol. 1997;8Suppl 2:101–104.

    Article  PubMed  Google Scholar 

  84. Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am J Clin Pathol. 1999;112:101–107.

    PubMed  CAS  Google Scholar 

  85. Lai R, Weiss LM, Chang KL et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol. 1999;111:488–494.

    PubMed  CAS  Google Scholar 

  86. Swerdlow SH. Small B-cell lymphomas of the lymph nodes and spleen: practical insights to diagnosis and pathogenesis. Mod Pathol. 1999;12:125–140.

    PubMed  CAS  Google Scholar 

  87. de Boer CJ, Schuuring E, Dreef E et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood. 1995;86:2715–2723.

    PubMed  Google Scholar 

  88. Swerdlow SH, Yang WI, Zukerberg LR et al. Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. Hum Pathol. 1995;26:999–1004.

    Article  PubMed  CAS  Google Scholar 

  89. Zukerberg LR, Yang WI, Arnold A et al. Cyclin D1 expression in non-Hodgkin’s lymphomas. Detection by immunohistochemistry. Am J Clin Pathol. 1995;103:756–760.

    PubMed  CAS  Google Scholar 

  90. de Boer CJ, Kluin-Nelemans JC, Dreef E et al. Involvement of the CCND1 gene in hairy cell leukemia. Ann Oncol. 1996;7:251–256.

    PubMed  Google Scholar 

  91. Bosch F, Campo E, Jares P et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol. 1995;91:1025–1030.

    PubMed  CAS  Google Scholar 

  92. Pruneri G, Fabris S, Baldini L et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol. 2000;156:1505–1513.

    PubMed  CAS  Google Scholar 

  93. Hernandez L, Fest T, Cazorla M et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351–3359.

    PubMed  CAS  Google Scholar 

  94. Pinyol M, Hernandez L, Cazorla M et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997;89:272–280.

    PubMed  CAS  Google Scholar 

  95. Williams ME, Whitefield M, Swerdlow SH. Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. Ann Oncol. 1997;8Suppl 2:71–73.

    Article  PubMed  Google Scholar 

  96. Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–2078.

    PubMed  CAS  Google Scholar 

  97. Swerdlow SH, Habeshaw JA, Murray LJ et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol. 1983;113:181–197.

    PubMed  CAS  Google Scholar 

  98. Ott G, Kalla J, Hanke A et al. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma. 1998;32:55–63.

    PubMed  CAS  Google Scholar 

  99. The Non-Hodgkin’s Lymphoma Classification Project. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin’s Lymphoma. Blood. 1997;89:3909–3918.

    Google Scholar 

  100. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311:1471–1475.

    Article  PubMed  CAS  Google Scholar 

  101. Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4:1470–1480.

    PubMed  CAS  Google Scholar 

  102. Ngan B, Warnke A, Cleary ML. Variability of immunoglobulin expression in follicular lymphoma. An immunohistologic and molecular genetic study. Am J Pathol. 1989;135:1139–1144.

    PubMed  CAS  Google Scholar 

  103. Kaufmann O, Flath B, Spath-Schwalbe E et al. Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Am J Clin Pathol. 1999;111:117–122.

    PubMed  CAS  Google Scholar 

  104. de Leon ED, Alkan S, Huang JC et al. Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin’s lymphomas of small lymphocytes. Mod Pathol. 1998;11:1046–1051.

    PubMed  Google Scholar 

  105. Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol. 1997;10:859–863.

    PubMed  CAS  Google Scholar 

  106. Scoazec JY, Berger F, Magaud JP et al. The dendritic reticulum cell pattern in B cell lymphomas of the small cleaved, mixed, and large cell types: an immunohistochemical study of 48 cases. Hum Pathol. 1989;20:124–131.

    Article  PubMed  CAS  Google Scholar 

  107. de Leval L, Harris NL, Longtine J et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol. 2001;25:732–741.

    Article  PubMed  Google Scholar 

  108. Lai R, Arber DA, Chang KL et al. Frequency of bcl-2 expression in non-Hodgkin’s lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol. 1998;11:864–869.

    PubMed  CAS  Google Scholar 

  109. Horsman DE, Gascoyne RD, Coupland RW et al. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol. 1995;103:472–478.

    PubMed  CAS  Google Scholar 

  110. Knutsen T. Cytogenetic mechanisms in the pathogenesis and progression of follicular lymphoma. Cancer Surv. 1997;30:163–192.

    PubMed  CAS  Google Scholar 

  111. Horsman DE, Okamoto I, Ludkovski O et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol. 2003;120:424–433.

    Article  PubMed  Google Scholar 

  112. Bergman R, Kurtin PJ, Gibson LE et al. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol. 2001;137:432–439.

    PubMed  CAS  Google Scholar 

  113. Yang B, Tubbs RR, Finn W et al. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am J Surg Pathol. 2000;24:694–702.

    Article  PubMed  CAS  Google Scholar 

  114. Maes B, Wolf-Peeters C. Marginal zone cell lymphoma-an update on recent advances. Histopathology. 2002;40:117–126.

    Article  PubMed  CAS  Google Scholar 

  115. Ortiz-Hidalgo C, Wright DH. The morphological spectrum of monocytoid B-cell lymphoma and its relationship to lymphomas of mucosa-associated lymphoid tissue. Histopathology. 1992;21:555–561.

    Article  PubMed  CAS  Google Scholar 

  116. Nizze H, Cogliatti SB, von Schilling C et al. Monocytoid B-cell lymphoma: morphological variants and relationship to low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue. Histopathology. 1991;18:403–414.

    Article  PubMed  CAS  Google Scholar 

  117. Garcia DP, Rooney MT, Ahmad E et al. Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. Am J Clin Pathol. 2001;115:258–265.

    Article  PubMed  CAS  Google Scholar 

  118. Kurtin PJ, Hobday KS, Ziesmer S et al. Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol. 1999;112:319–329.

    PubMed  CAS  Google Scholar 

  119. Flenghi L, Bigerna B, Fizzotti M et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol. 1996;148:1543–1555.

    PubMed  CAS  Google Scholar 

  120. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–2795.

    PubMed  CAS  Google Scholar 

  121. Hammer RD, Glick AD, Greer JP et al. Splenic marginal zone lymphoma. A distinct B-cell neoplasm. Am J Surg Pathol. 1996;20:613–626.

    Article  PubMed  CAS  Google Scholar 

  122. Isaacson PG, Piris MA, Catovksy D et al. Splenic marginal zone lymphoma. In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.”(Jaffe E.S., Harris N.L., Stein H. et al., eds.)135–137. IARC Press, Lyon, 2001.

    Google Scholar 

  123. Campo E, Miquel R, Krenacs L et al. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol. 1999;23:59–68.

    Article  PubMed  CAS  Google Scholar 

  124. Isaacson PG, Matutes E, Burke M et al. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994;84:3828–3834.

    PubMed  CAS  Google Scholar 

  125. Matutes E, Morilla R, Owusu-Ankomah K et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994;83:1558–1562.

    PubMed  CAS  Google Scholar 

  126. Mollejo M, Lloret E, Menarguez J et al. Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features. Am J Surg Pathol. 1997;21:772–780.

    Article  PubMed  CAS  Google Scholar 

  127. Matutes E, Morilla R, Owusu-Ankomah K et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14Suppl 1:57–61.

    PubMed  Google Scholar 

  128. Camacho FI, Mollejo M, Mateo MS et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268–1276.

    Article  PubMed  CAS  Google Scholar 

  129. Gruszka-Westwood AM, Hamoudi RA, Matutes E et al. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood. 2001;97:3552–3558.

    Article  PubMed  CAS  Google Scholar 

  130. Sheibani K, Sohn CC, Burke JS et al. Monocytoid B-cell lymphoma. A novel B-cell neoplasm. Am J Pathol. 1986;124:310–318.

    PubMed  CAS  Google Scholar 

  131. Piris MA, Rivas C, Morente M et al. Monocytoid B-cell lymphoma, a tumour related to the marginal zone. Histopathology. 1988;12:383–392.

    Article  PubMed  CAS  Google Scholar 

  132. Cousar JB, McGinn DL, Glick AD et al. Report of an unusual lymphoma arising from parafollicular B-lymphocytes (PBLs) or so-called “monocytoid” lymphocytes. Am J Clin Pathol. 1987;87:121–128.

    PubMed  CAS  Google Scholar 

  133. Doglioni C, Wotherspoon AC, Moschini A et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet. 1992;339:834–835.

    Article  PubMed  CAS  Google Scholar 

  134. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992;102:1628–1638.

    PubMed  CAS  Google Scholar 

  135. White WL, Ferry JA, Harris NL et al. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology. 1995;102:1994–2006.

    PubMed  CAS  Google Scholar 

  136. Hsi ED, Zukerberg LR, Schnitzer B et al. Development of extrasalivary gland lymphoma in myoepithelial sialadenitis. Mod Pathol. 1995;8:817–824.

    PubMed  CAS  Google Scholar 

  137. Bailey EM, Ferry JA, Harris NL et al. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol. 1996;20:1011–1023.

    Article  PubMed  CAS  Google Scholar 

  138. Eidt S, Stolte M, Fischer R. Helicobacter pylori gastritis and primary gastric non-Hodgkin’s lymphomas. J Clin Pathol. 1994;47:436–439.

    Article  PubMed  CAS  Google Scholar 

  139. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338:1175–1176.

    Article  PubMed  CAS  Google Scholar 

  140. Ferreri AJM, Guidoboni M, Ponzoni M et al. Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. J Natl Cancer Inst. 2004;96:586–594.

    PubMed  Google Scholar 

  141. Royer B, Cazals-Hatem D, Sibilia J et al. Lymphomas in patients with Sjogren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90:766–775.

    PubMed  CAS  Google Scholar 

  142. Kassan SS, Thomas TL, Moutsopoulos HM et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888–892.

    PubMed  CAS  Google Scholar 

  143. Kato I, Tajima K, Suchi T et al. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. Jpn J Cancer Res. 1985;76:1085–1090.

    PubMed  CAS  Google Scholar 

  144. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312:601–604.

    Article  PubMed  CAS  Google Scholar 

  145. Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology. 1987;11:445–462.

    Article  PubMed  CAS  Google Scholar 

  146. Isaacson PG, Muller-Hermelink HK, Piris MA et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.”(Jaffe E.S., Harris N.L., Stein H. et al., eds.)157–160. IARC Press, Lyon, 2001.

    Google Scholar 

  147. Ballesteros E, Osborne BM, Matsushima AY. CD5+ low-grade marginal zone B-cell lymphomas with localized presentation. Am J Surg Pathol. 1998;22:201–207.

    Article  PubMed  CAS  Google Scholar 

  148. Ferry JA, Yang WI, Zukerberg LR et al. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31–37.

    PubMed  CAS  Google Scholar 

  149. Wenzel C, Dieckmann K, Fiebiger W et al. CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. Leuk Lymphoma. 2001;42:823–829.

    PubMed  CAS  Google Scholar 

  150. Chen LT, Lin JT, Shyu RY et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol. 2001;19:4245–4251.

    PubMed  CAS  Google Scholar 

  151. Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–577.

    Article  PubMed  CAS  Google Scholar 

  152. Streubel B, Simonitsch-Klupp I, Mullauer L et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18:1722–1726.

    Article  PubMed  CAS  Google Scholar 

  153. Dierlamm J, Baens M, Wlodarska I et al. The Apoptosis Inhibitor Gene API2 and a Novel 18q Gene, MLT, Are Recurrently Rearranged in the t(11;18)(q21;q21) Associated With Mucosa-Associated Lymphoid Tissue Lymphomas. Blood. 1999;93:3601–3609.

    PubMed  CAS  Google Scholar 

  154. Liu H, Ye H, Ruskone-Fourmestraux A et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122:1286–1294.

    Article  PubMed  CAS  Google Scholar 

  155. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39–40.

    Article  PubMed  CAS  Google Scholar 

  156. Streubel B, Lamprecht A, Dierlamm J et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335–2339.

    Article  PubMed  CAS  Google Scholar 

  157. Willis TG, Jadayel DM, Du MQ et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96:35–45.

    Article  PubMed  CAS  Google Scholar 

  158. Liu H, Ye H, Dogan A et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood. 2001;98:1182–1187.

    Article  PubMed  CAS  Google Scholar 

  159. Remstein ED, Kurtin PJ, James CD et al. Mucosa-Associated Lymphoid Tissue Lymphomas with t(11;18)(q21;q21) and Mucosa-Associated Lymphoid Tissue Lymphomas with Aneuploidy Develop Along Different Pathogenetic Pathways. Am J Pathol. 2002;161:63–71.

    PubMed  Google Scholar 

  160. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 1990;50:3605–3609.

    PubMed  CAS  Google Scholar 

  161. Frassoldati A, Lamparelli T, Federico M et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma. 1994;13:307–316.

    Article  PubMed  CAS  Google Scholar 

  162. Flandrin G, Sigaux F, Sebahoun G et al. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol. 1984;11:458–471.

    PubMed  CAS  Google Scholar 

  163. Bouroncle BA. Leukemic reticuloendotheliosis (hairy cell leukemia). Blood. 1979;53:412–436.

    PubMed  CAS  Google Scholar 

  164. Seshadri RS, Brown EJ, Zipursky A. Leukemic reticuloendotheliosis. A failure of monocyte production. N Engl J Med. 1976;295:181–184.

    Article  PubMed  CAS  Google Scholar 

  165. Ahmad E, Garcia D, Davis BH. Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification. Cytometry. 2002;50:1–7.

    Article  PubMed  CAS  Google Scholar 

  166. Salomon-Nguyen F, Valensi F, Troussard X et al. The value of the monoclonal antibody, DBA44, in the diagnosis of B-lymphoid disorders. Leuk Res. 1996;20:909–913.

    Article  PubMed  CAS  Google Scholar 

  167. Yaziji H, Janckila AJ, Lear SC et al. Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. Am J Clin Pathol. 1995;104:397–402.

    PubMed  CAS  Google Scholar 

  168. Burkitt D, A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218–223.

    Article  PubMed  CAS  Google Scholar 

  169. Soussain C, Patte C, Ostronoff M et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85:664–674.

    PubMed  CAS  Google Scholar 

  170. Levine PH, Kamaraju LS, Connelly RR et al. The American Burkitt’s Lymphoma Registry: eight years’ experience. Cancer. 1982;49:1016–1022.

    Article  PubMed  CAS  Google Scholar 

  171. Philip T, Lenoir GM, Bryon PA et al. Burkitt-type lymphoma in France among non-Hodgkin malignant lymphomas in Caucasian children. Br J Cancer. 1982;45:670–678.

    PubMed  CAS  Google Scholar 

  172. Diebold J, Jaffe ES, Raphael M et al. Burkitt lymphoma. In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues”. (Jaffe E.S., Harris N.L., Stein H. et al., eds.) 181–184. IARC Press, Lyon, 2001.

    Google Scholar 

  173. Braziel RM, Arber DA, Slovak ML et al. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood. 2001;97:3713–3720.

    Article  PubMed  CAS  Google Scholar 

  174. Hui PK, Feller AC, Lennert K. High-grade non-Hodgkin’s lymphoma of B-cell type. I. Histopathology. Histopathology. 1988;12:127–143.

    Article  PubMed  CAS  Google Scholar 

  175. Spina D, Leoncini L, Megha T et al. Cellular kinetic and phenotypic heterogeneity in and among Burkitt’s and Burkitt-like lymphomas. J Pathol. 1997;182:145–150.

    Article  PubMed  CAS  Google Scholar 

  176. Chadburn A, Knowles DM. Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B-or T-cell lineage of 95% of diffuse aggressive non-Hodgkin’s lymphomas. Am J Clin Pathol. 1994;102:284–291.

    PubMed  CAS  Google Scholar 

  177. Fingeroth JD, Weis JJ, Tedder TF et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984;81:4510–4514.

    Article  PubMed  CAS  Google Scholar 

  178. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood. 1994;84:1361–1392.

    PubMed  CAS  Google Scholar 

  179. Hamilton-Dutoit SJ, Raphael M, Audouin J et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993;82:619–624.

    PubMed  CAS  Google Scholar 

  180. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12:200–217.

    PubMed  CAS  Google Scholar 

  181. Prevot S, Hamilton-Dutoit S, Audouin J et al. Analysis of African Burkitt’s and high-grade B cell non-Burkitt’s lymphoma for Epstein-Barr virus genomes using in situ hybridization. Br J Haematol. 1992;80:27–32.

    PubMed  CAS  Google Scholar 

  182. Tao Q, Robertson KD, Manns A et al. Epstein-Barr virus (EBV) in endemic Burkitt’s lymphoma: molecular analysis of primary tumor tissue. Blood. 1998;91:1373–1381.

    PubMed  CAS  Google Scholar 

  183. Anwar N, Kingma DW, Bloch AR et al. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt’s lymphoma from Egypt: epidemiologic correlations. Cancer. 1995;76:1245–1252.

    Article  PubMed  CAS  Google Scholar 

  184. Gutierrez MI, Bhatia K, Barriga F et al. Molecular epidemiology of Burkitt’s lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood. 1992;79:3261–3266.

    PubMed  CAS  Google Scholar 

  185. Zech L, Haglund U, Nilsson K et al. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17:47–56.

    Article  PubMed  CAS  Google Scholar 

  186. Bernheim A, Berger R, Lenoir G. Cytogenetic studies on African Burkitt’s lymphoma cell lines: t(8;14), t(2;8) and t(8;22) translocations. Cancer Genet Cytogenet. 1981;3:307–315.

    Article  PubMed  CAS  Google Scholar 

  187. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood. 1994;84:1361–1392.

    PubMed  CAS  Google Scholar 

  188. Gatter KC, Warnke A. Diffuse large B-cell lymphoma. In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.” (Jaffe E.S., Harris N.L., Stein H. et al., eds.) 171–176. IARC Press, Lyon, 2001.

    Google Scholar 

  189. Armitage JO, Dick FR, Corder MP. Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat Rep. 1981;65:413–418.

    PubMed  CAS  Google Scholar 

  190. Delabie J, Vandenberghe E, Kennes C et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin’s disease, paragranuloma subtype. Am J Surg Pathol. 1992;16:37–48.

    Article  PubMed  CAS  Google Scholar 

  191. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol. 1988;12:433–443.

    PubMed  CAS  Google Scholar 

  192. Wang J, Sun NC, Chen YY et al. T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Displays a Heterogeneity Similar to Diffuse Large B-Cell Lymphoma: A Clinicopathologic, Immunohistochemical, and Molecular Study of 30 Cases. Appl Immunohistochem Mol Morphol. 2005;13:109–115.

    Article  PubMed  Google Scholar 

  193. Nador RG, Cesarman E, Chadburn A et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–656.

    PubMed  CAS  Google Scholar 

  194. Banks PM, Warnke RA. Mediastinal (thymic) large B-cell lymphoma. In “World Health Organization Classification of Tumours. Patholoy and Genetics of Tumours of Haematopoietic and Lymphopid Tissues.” (Jaffe E.S., Harris N.L., Stein H. et al., eds.) 175–176. IARC Press., Lyon, 2001.

    Google Scholar 

  195. Kirn D, Mauch P, Shaffer K et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993;11:1336–1343.

    PubMed  CAS  Google Scholar 

  196. Moller P, Lammler B, Eberlein-Gonska M et al. Primary mediastinal clear cell lymphoma of B-cell type. Virchows Arch A Pathol Anat Histopathol. 1986;409:79–92.

    Article  PubMed  CAS  Google Scholar 

  197. Kennedy GA, Cull G, Gill D et al. Identification of tumours with the CD43 only phenotype during the investigation of suspected lymphoma: a heterogeneous group not necessarily of T cell origin. Pathology. 2002;34:46–50.

    Article  PubMed  Google Scholar 

  198. Doggett RS, Wood GS, Horning S et al. The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol. 1984;115:245–252.

    PubMed  CAS  Google Scholar 

  199. Stein H, Lennert K, Feller AC et al. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res. 1984;42:67–147.

    Article  PubMed  CAS  Google Scholar 

  200. Bernard M, Gressin R, Lefrere F et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001;15:1785–1791.

    Article  PubMed  CAS  Google Scholar 

  201. Dunphy CH, Wheaton SE, Perkins SL. CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic transformations of mantle cell lymphoma. Mod Pathol. 1997;10:818–822.

    PubMed  CAS  Google Scholar 

  202. Kroft SH, Dawson DB, McKenna RW. Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases. Am J Clin Pathol, 2001;115:385–395.

    Article  PubMed  CAS  Google Scholar 

  203. Yamaguchi M, Seto M, Okamoto M et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99:815–821.

    Article  PubMed  CAS  Google Scholar 

  204. Harada S, Suzuki R, Uehira K et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5-with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13:1441–1447.

    Article  PubMed  CAS  Google Scholar 

  205. Barrans SL, Carter I, Owen RG et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99:1136–1143.

    Article  PubMed  CAS  Google Scholar 

  206. Kramer MH, Hermans J, Parker J et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol. 1996;14:2131–2138.

    PubMed  CAS  Google Scholar 

  207. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.

    Article  PubMed  CAS  Google Scholar 

  208. Grogan TM, Van Camp B, Kyle RA et al. Plasma cell neoplasms. In “Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.” (Jaffe E.S., Harris N.L., Stein H. et al., eds.) 142–156. IARC Press, Lyon, 2001.

    Google Scholar 

  209. Young JL, Jr., Percy CL, Asire AJ et al. Cancer incidence and mortality in the United States, 1973–77. Natl Cancer Inst Monogr. 1981;1–187.

    Google Scholar 

  210. Grogan TM, Spier C. B-cell immunoproliferative disorders, including multiple myeloma and amyloidosis. In “Neoplastic Hematopathology” 1557–1587. Lippincott Williams & Wilkins, Philadelphia, 2001.

    Google Scholar 

  211. Bartl R, Frisch B, Burkhardt R et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51:361–375.

    PubMed  CAS  Google Scholar 

  212. Greipp PR, Leong T, Bennett JM et al. Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507.

    PubMed  CAS  Google Scholar 

  213. Kronland R, Grogan T, Spier C et al. Immunotopographic assessment of lymphoid and plasma cell malignancies in the bone marrow. Hum Pathol. 1985;16:1247–1254.

    Article  PubMed  CAS  Google Scholar 

  214. Robillard N, Avet-Loiseau H, Garand R et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102:1070–1071.

    Article  PubMed  CAS  Google Scholar 

  215. Mahmoud MS, Huang N, Nobuyoshi M et al. Altered expression of Pax-5 gene in human myeloma cells. Blood. 1996;87:4311–4315.

    PubMed  CAS  Google Scholar 

  216. Lima M, Teixeira MA, Fonseca S et al. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. Blood Cells Mol Dis. 2000;26:634–645.

    Article  PubMed  CAS  Google Scholar 

  217. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160:1293–1299.

    PubMed  Google Scholar 

  218. Van Camp B, Durie BG, Spier C et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990;76:377–382.

    PubMed  Google Scholar 

  219. Beschorner R, Horny HP, Petruch UR et al. Frequent expression of haemopoietic and non-haemopoietic antigens by reactive plasma cells: an immunohistochemical study using formalin-fixed, paraffin-embedded tissue. Histol Histopathol. 1999;14:805–812.

    PubMed  CAS  Google Scholar 

  220. Pileri S, Poggi S, Baglioni P et al. Histology and immunohistology of bone marrow biopsy in multiple myeloma. Eur J Haematol Suppl. 1989;51:52–59.

    PubMed  CAS  Google Scholar 

  221. Knowles DM. B-cell immunoproliferative disorders. In “Neoplastic Hematopathology.” (Knowles D.M., ed.) Lippincott Williams & Wilkins, Philadelphia, 2001.

    Google Scholar 

  222. Alexandrakis MG, Passam FH, Kyriakou DS et al. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol. 2004;27:8–13.

    Article  PubMed  Google Scholar 

  223. Garcia-Sanz R, Gonzalez-Fraile MI, Mateo G et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer. 2004;112:884–889.

    Article  PubMed  CAS  Google Scholar 

  224. Drach J, Ackermann J, Fritz E et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–809.

    PubMed  CAS  Google Scholar 

  225. Soverini S, Cavo M, Cellini C et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102:1588–1594.

    Article  PubMed  CAS  Google Scholar 

  226. Chesi M, Brents LA, Ely SA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 2001;97:729–736.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY

    April Chiu MD & Amy Chadburn MD

Authors
  1. April Chiu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy Chadburn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Lymphoma and Myeloma, Weill Medical College of Cornell University The New York Presbyterian Hospital, New York, New York

    John P. Leonard MD  & Morton Coleman MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chiu, A., Chadburn, A. (2006). Pathology of B-Cell Non-Hodgkin’s Lymphomas and Multiple Myeloma. In: Leonard, J.P., Coleman, M. (eds) Hodgkin’s and Non-Hodgkin’s Lymphoma. Cancer Treatment and Research, vol 131. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-29346-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-29346-2_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-29345-5

  • Online ISBN: 978-0-387-29346-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation